-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Speaking of DRG/DIP, we must talk about the "Notice on Printing and Distributing the Three-Year Action Plan for the Reform of DRG/DIP Payment Methods" (Medical Insurance [2021] .
It can be seen that the DRG/DIP payment reform in the next three years is likely to affect the drug structure of the public medical institution mark.
"Three doctors" policy linkage support
Innovative drugs are drugs that solve major diseases, have better clinical treatment effects, and have better effects after a large number of clinical trials have been compared with first-line treatment dru.
From this perspective, no matter how the medical insurance payment is reformed, allowing the people to use the best medicines, saving lives and prolonging the survival of patients will be an important direction for China's future medical refo.
For example, the new version of the Essential Medicines List will pay more attention to highlighting the clinical value of drugs in the selecti.
With the in-depth development of the reform of the medical system, China's "three medical" policies have shown a closer linkage, and all-round support is provided for innovative drugs included in the medical insurance negotiation catal.
It is necessary to change the project strategy
On the other hand, you need to pay attention to the 4 drafts for comments issued by the Center for Drug Evaluation of the State Drug Administration on July 2, 202 In particular, the "Technical Requirements for Pharmaceutical Common Issues at the Pre-marketing Application Meeting for Innovative Chemical Drugs (Draft for Comment)" and the "Guidelines for Clinical Research and Development of Antitumor Drugs Oriented to Clinical Value (Draft for Comment)" require that new drugs be used before marketing applicatio.
To sum up, the purpose of DRG/DIP payment reform is to rationalize drug use and ensure people's heal.
In order to meet the relevant requirements of China's pharmaceutical system reform, it is suggested that domestic pharmaceutical companies should focus on clinical value in the establishment of new drug research and development projects to achieve "Me-too" to "Me-Better", and even "First-In-Class" and "M.
Editor in charge : Yu Rujin
Source: Editing Center
